- Exchange: NASDAQ GM
- Sector: Consumer, Non-cyclical
- Industry: Biotechnology
- Sub-Industry: Medical-Biomedical/Gene
Ligand Pharmaceuticals Inc
+ Add to WatchlistLGND:US
27.9500 USD 0.5700 2.08%As of 20:10:00 ET on 05/23/2013.
Snapshot for Ligand Pharmaceuticals Inc (LGND)
| Open: | 26.8800 | Day's Range: | 26.3100 - 28.4300 | Volume: | 128,902 |
|---|---|---|---|---|---|
| Previous Close: | 27.9500 | 52wk Range: | 1,128.0000 - 2,992.0000 | 1-Yr Rtn: | +119.73% |
Key Statistics for LGND
| Current P/E Ratio (ttm) | - |
|---|---|
| Estimated P/E(12/2013) | 49.9107 |
| Relative P/E vs. SPX | - |
| Earnings Per Share (USD) (ttm) | 0.0000 |
| Est. EPS (USD) (12/2013) | 0.5600 |
| Est. PEG Ratio | 1.7211 |
| Market Cap (M USD) | 565.57 |
| Shares Outstanding (M) | 20.23 |
| 30 Day Average Volume | 161,143 |
| Price/Book (mrq) | 18.4756 |
| Price/Sale (ttm) | 14.9587 |
| Dividend Indicated Gross Yield | -% |
| Cash Dividend (USD) | 15.0000 |
| Last Dividend | 04/03/2007 |
| 5 Year Dividend Growth | - |
| Next Earnings Announcement | 08/08/2013 |
mrq = Most Recent Quarter; ttm = Trailing Twelve Months
Income Statement for LGND
Company Profile & Key Executives for LGND
Ligand Pharmaceuticals Incorporated develops drugs which regulate hormone activated intracellular receptors. These receptors play a role in regulating the genetic processes affecting diseases such as gynecological disorders, certain cancers, as well as cardiovascular, inflammatory, and skin diseases.
| John L HigginsPresident/CEO | Mathew W Foehr "Matt"Exec VP/COO |
| John P SharpVP:Finance/CFO | Charles S BerkmanVP/Secretary/General Counsel |
Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.
Sponsored Financial Commentaries
Advertisement
Top Forex Trading Resources
-
LGND News
-
Industry News
Advertisement
Advertisement
Sponsored Links
Advertisements
Rate this Page